IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1151-1175 out of 1240.

<< < 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

Public Release: 8-May-2014
Molecular Cancer Research
New paper provides important insights into carcinoma-associated fibroblasts
A new paper by a team of researchers led by Zachary T. Schafer, Coleman Assistant Professor of Cancer Biology in the Department of Biological Sciences at the University of Notre Dame, offers important new insights into the role carcinoma-associated fibroblasts (CAFs) play in tumor biology. A number of recent studies have revealed CAFs to be a major contributor to tumor progression through a variety of mechanisms. Despite this information, the precise role CAFs play in augmenting the growth of tumors is still poorly understood.
V Foundation for Cancer Research

Contact: Zachary T. Schafer
zschafe1@nd.edu
574-631-0875
University of Notre Dame

Public Release: 8-May-2014
Chemistry & Biology
New technology using florescent proteins tracks cancer cells circulating in the blood
After cancer spreads, finding and destroying malignant cells that circulate in the body is usually critical to patient survival. Now, researchers reporting in the Cell Press journal Chemistry & Biology have developed a new method that allows investigators to label and track single tumor cells circulating in the blood. This advance could help investigators develop a better understanding of cancer spread and how to stop it.

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Public Release: 8-May-2014
PLOS Genetics
Exact outline of melanoma could lead to new diagnostic tools, therapies
Researchers have identified a specific biochemical process that can cause normal and healthy skin cells to transform into cancerous melanoma cells, which should help predict melanoma vulnerability and could also lead to future therapies. They discovered in this situation that the immune system is getting thrown into reverse, helping to cause cancer instead of preventing it.
National Institutes of Health

Contact: Arup Indra
arup.indra@oregonstate.edu
541-737-5775
Oregon State University

Public Release: 8-May-2014
Science Signaling
Chemotherapy timing is key to success
Nanoparticles that stagger delivery of two drugs knock out aggressive tumors.

Contact: Andrew Carleen
acarleen@mit.edu
617-253-1682
Massachusetts Institute of Technology

Public Release: 8-May-2014
Journal of Clinical Oncology
Experimental antibody shows early promise for treatment of childhood tumor
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
National Institutes of Health, St. Baldrick's Foundation, ALSAC, and others

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital

Public Release: 8-May-2014
Immunity
Immune cells found to fuel colon cancer stem cells
A subset of immune cells directly target colon cancers, rather than the immune system, giving the cells the aggressive properties of cancer stem cells, a new study finds.
NIH/National Cancer Institute

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 8-May-2014
Radiotherapy & Oncology
Wake Forest Baptist finds success with novel lung cancer treatment
An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade.

Contact: Bonnie Davis
bdavis@wakehealth.edu
336-716-4977
Wake Forest Baptist Medical Center

Public Release: 8-May-2014
Journal of Community Genetics
Few women at high-risk for hereditary breast and ovarian cancer receive genetic counseling
Mutations in the BRCA1 and BRCA2 genes account for nearly 25 percent of hereditary breast cancers and most hereditary ovarian cancers, yet a study by cancer prevention and control researchers at Virginia Commonwealth University Massey Cancer Center suggests an alarmingly small amount of women who qualify for BRCA genetic counseling actually receive the services. Additionally, they found that a significant proportion of women with a family history of breast and ovarian cancer underestimate their risk.
NIH/National Cancer Institute

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 8-May-2014
Cell Reports
How immune cells use steroids
Researchers at the European Bioinformatics Institute and the Wellcome Trust Sanger Institute have discovered that some immune cells turn themselves off by producing a steroid. The findings, published in Cell Reports, have implications for the study of cancers, autoimmune diseases and parasitic infections.
European Research Council

Contact: Sonia Furtado Neves
pressoffice@embl.de
49-622-138-78263
European Molecular Biology Laboratory

Public Release: 8-May-2014
Journal of Cell Science
Ovarian cancer cells are more aggressive on soft tissues
When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut. A new study has found that ovarian cancer cells are more aggressive on these soft tissues due to the mechanical properties of this environment. The finding is contrary to what is seen with other malignant cancer cells that seem to prefer stiffer tissues.
National Science Foundation, Georgia Tech, Emory Center for Regenerative Medicine

Contact: Brett Israel
brett.israel@comm.gatech.edu
404-385-1933
Georgia Institute of Technology

Public Release: 7-May-2014
2014 SID Annual Meeting
Regular doctor visits may greatly diminish skin cancer deaths
The risk of dying from the most dangerous type of skin cancer is significantly reduced with regular doctor visits, according to a Henry Ford Hospital study. This is believed to be the first study of its kind to link melanoma mortality with routine health care use.
Henry Ford Hospital, Henry Ford Medical Group and Dermatology Foundation

Contact: David Olejarz
David.Olejarz@hfhs.org
313-874-4094
Henry Ford Health System

Public Release: 7-May-2014
Nature Cell Biology
Vascular simulation research reveals new mechanism that switches in disease
New clues to endothelial cell behavior are emerging from vascular simulation research. Recent papers from the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center focus on this interdisciplinary field.

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center

Public Release: 7-May-2014
IMPAKT 2014 Breast Cancer Conference
International molecular screening program for metastatic breast cancer AURORA at IMPAKT
AURORA is the first international research program of its kind aiming to improve the lives of patients with metastatic breast cancer. Recently launched by the Breast International Group, it will be presented by Martine Piccart-Gebhart at the IMPAKT Breast Cancer Conference on Saturday, May 10, during a session devoted to new drugs and trials.

Contact: Cecilia Waldvogel
cecilia.waldvogel@bigagainstbc.org
Breast International Group (BIG)-aisbl

Public Release: 7-May-2014
2014 ARRS Annual Meeting
Breast tomosynthesis after screening mammography reduces need for ultrasound, biopsies
Breast tomosynthesis in the diagnostic workup for one- or two-view focal asymmetry detected at screening mammography resulted in less use of ultrasound, fewer biopsies, and higher positive predictive value for cancer than when diagnostic exams involved only 2-D mammography.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
American Roentgen Ray Society

Public Release: 7-May-2014
Journal of the Americal Chemical Society
Researchers use DNA to build tool that may literally shine light on cancer
Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-566-3813
University of Montreal

Public Release: 7-May-2014
2014 ARRS Annual Meeting
Nonscreened patients with breast cancer need more treatment than screened patients
Screening 40- to 49-year-old women for breast cancer has additional benefits beyond the proven decrease in mortality rate.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
American Roentgen Ray Society

Public Release: 7-May-2014
2014 ARRS Annual Meeting
CT-guided irreversible electroporation safe in unresectable pancreatic carcinoma
A small group of patients with locally advanced unresectable pancreatic carcinoma suffered no major ill effects -- pancreatitis or fistula formation -- after undergoing percutaneous CT-guided irreversible electroporation.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
American Roentgen Ray Society

Public Release: 7-May-2014
Journal of Clinical Investigation
Pushing the boundaries of stem cells
Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood stems cells to generate in greater numbers making them more useful in adult transplantation.
Empire State Stem Cell Board

Contact: Lucia Lee
NewsMedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 7-May-2014
2014 ARRS Annual Meeting
Overestimation of radiation exposure may keep women from critical screening
Misinformation and misunderstanding about the risks associated with ionizing radiation create heightened public concern and fear, and may result in avoidance of screening mammography that can detect early cancers.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
American Roentgen Ray Society

Public Release: 7-May-2014
2014 ARRS Annual Meeting
Glutamate imaging better than MR spectroscopy in first 3 hours after ischemic stroke
Glutamate imaging reveals ischemic lesions in the first three hours after stroke that are not distinguishable in T1-weighted and T2-weighted imaging.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
American Roentgen Ray Society

Public Release: 6-May-2014
ACS Nano
Two-lock box delivers cancer therapy
Rice University scientists have designed a tunable virus that works like a safe deposit box. It takes two keys to open it and release its therapy for cancer and other diseases.

Contact: David Ruth
david@rice.edu
713-348-6327
Rice University

Public Release: 6-May-2014
Stem Cell Reports
Ability to isolate and grow breast tissue stem cells could speed cancer research
By carefully controlling the levels of two proteins, researchers at the Salk Institute have discovered how to keep mammary stem cells -- those that can form breast tissue -- alive and functioning in the lab. The new ability to propagate mammary stem cells is allowing them to study both breast development and the formation of breast cancers.

Contact: Chris Emery
Cemery@salk.edu
858-453-4100
Salk Institute

Public Release: 6-May-2014
Preventive Medicine
College kids need to change unhealthy ways
A new study from Northwestern Medicine and Northeastern Illinois University found that the majority of college students are engaging in unhealthy behaviors that could increase their risk of cancer later on.
NIH/National Cancer Institute

Contact: Erin White
ewhite@northwestern.edu
847-491-4888
Northwestern University

Public Release: 5-May-2014
Canadian Journal of Cardiology
Hypertension related to new cancer therapies -- a new syndrome emerges
New cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signaling, have improved the outlook for patients with some cancers and are now used as a first line therapy for some tumors. However, almost 100 percent of patients who take VEGF inhibitors (VEGFIs) develop high blood pressure, and a subset develops severe hypertension. The mechanisms underlying VEGF inhibitor-induced hypertension need to be better understood and there is a need for clear guidelines and improved management, say investigators.

Contact: Eileen Leahy
cjcmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 5-May-2014
Annals of Internal Medicine
WHI reports $37.1 billion economic return on combined hormone therapy clinical trial
The overall economic return from the Women's Health Initiative E+P trial indicates that changes in practice stemming from the trial provided a net economic return of $37.1 billion over the 10-year period since the main findings were published.

Contact: Michael Nank
mnank@fredhutch.org
206-667-6906
Fred Hutchinson Cancer Research Center

Showing releases 1151-1175 out of 1240.

<< < 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

  Search News Releases

     

 

EurekAlert!